How harmless is FFA enhancement?
- PMID: 8980917
- DOI: 10.1007/BF03189715
How harmless is FFA enhancement?
Abstract
Standard heparin as well as low molecular weight heparin (LMWH) increase lipid levels in serum. It has been reported that a diet rich in long chain saturated fatty acids can enhance the susceptibility to experimental thrombosis. The mechanism by which serum fatty acids may provoke thrombosis is not clear. It is possible that the fatty acids change the properties of the cell membrane and thereby modify the response of platelets to aggregating agents. Heparin and its LMW fractions, by mobilising lipoprotein lipase that hydrolyses serum triglycerides (TG), cause the serum TG to increase, a well known "clearing effect' of heparin in turbid lipemic plasma. This effect may have no significance when it lasts for a short time; however, a long-lasting heparin effect on TG serum levels may have important consequences. The purpose of this study was to examine the time span of the action of heparin and its fractions and to investigate variations in the concentration of digoxin, which is a compound with narrow therapeutic width. The investigated substances after 2 days administration, provoked serum concentration increases of free fatty acids (FFA), TG and HDL-C. Seven days after stopping drug administration, FFA and HDL-C levels remained high, while triglycerides declined. Serum total cholesterol remained unchanged throughout. Digoxin levels increased non-significantly after heparin administration and during swimming stress, while a lipid diet caused a serum digoxin concentration increase.
Similar articles
-
Effect of increased uptake of plasma fatty acids by the liver on lipid metabolism in the hepatocellular nuclei.Prostaglandins Leukot Essent Fatty Acids. 1997 Jul;57(1):27-31. doi: 10.1016/s0952-3278(97)90489-0. Prostaglandins Leukot Essent Fatty Acids. 1997. PMID: 9250605
-
[Glucocorticoid-induced hypertiglyceridemia: effects of cortisone acetate on triglyceride secretion rates and post-heparin lipolytic activity in rabbits (author's transl)].Nihon Naibunpi Gakkai Zasshi. 1978 Mar 20;54(3):203-18. doi: 10.1507/endocrine1927.54.3_203. Nihon Naibunpi Gakkai Zasshi. 1978. PMID: 206474 Japanese.
-
Pharmacokinetic aspects of digoxin in patients with terminal renal failure III. Effect of heparin.Int J Clin Pharmacol Biopharm. 1977 Dec;15(12):560-2. Int J Clin Pharmacol Biopharm. 1977. PMID: 598950
-
Hemodialysis and cell toxicity in vitro related to plasma triglycerides, post-heparin lipolytic activity and free fatty acids.Acta Med Scand. 1984;216(1):75-83. doi: 10.1111/j.0954-6820.1984.tb03774.x. Acta Med Scand. 1984. PMID: 6485883
-
Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis.Thyroid. 1996 Apr;6(2):79-83. doi: 10.1089/thy.1996.6.79. Thyroid. 1996. PMID: 8733876 Clinical Trial.
Cited by
-
Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen.Eur J Drug Metab Pharmacokinet. 2005 Jul-Sep;30(3):171-4. doi: 10.1007/BF03190616. Eur J Drug Metab Pharmacokinet. 2005. PMID: 16250253
-
The role of the protein-binding on the mode of drug action as well the interactions with other drugs.Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):225-30. doi: 10.1007/BF03190876. Eur J Drug Metab Pharmacokinet. 2008. PMID: 19230595 Review.
-
Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations.Eur J Drug Metab Pharmacokinet. 2012 Mar;37(1):1-7. doi: 10.1007/s13318-011-0077-2. Epub 2011 Dec 16. Eur J Drug Metab Pharmacokinet. 2012. PMID: 22173744
-
Light induced changes in quinolone levels in rat serum and tissues.Eur J Drug Metab Pharmacokinet. 2004 Oct-Dec;29(4):231-3. doi: 10.1007/BF03190604. Eur J Drug Metab Pharmacokinet. 2004. PMID: 15726883
-
Changes in serum levels of quinolones in rats under the influence of experimental trauma.Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):73-8. doi: 10.1007/BF03190070. Eur J Drug Metab Pharmacokinet. 2000. PMID: 11112085
References
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous